Significant response to nivolumab for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case report

[1]  R. Shaco‐Levy,et al.  Rapid Response to Nivolumab in a Patient With Sarcomatoid Transformation of Chromophobe Renal Cell Carcinoma , 2017, Clinical genitourinary cancer.

[2]  Liang Cheng,et al.  Unclassified Renal Cell Carcinoma With Significant Response to Nivolumab , 2017, Clinical genitourinary cancer.

[3]  Charles Ferté,et al.  Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 , 2016, Clinical Cancer Research.

[4]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[5]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[6]  D. Geynisman.  Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. , 2015, European Urology.

[7]  M. Valsecchi.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[8]  T. Ho,et al.  PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation , 2015, Cancer Immunology Research.

[9]  I. Tannock,et al.  Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis. , 2015, European urology.

[10]  G. Freeman,et al.  PD-L1 expression in nonclear-cell renal cell carcinoma. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  J. Cheville,et al.  Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. , 2010, The Journal of urology.

[12]  Ming Zhou,et al.  Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. , 2009, Journal of Clinical Oncology.

[13]  J. Cheville,et al.  Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. , 2006, Cancer research.